Literature DB >> 26628469

Survival Impact of Increasing Time to Treatment Initiation for Patients With Head and Neck Cancer in the United States.

Colin T Murphy1, Thomas J Galloway2, Elizabeth A Handorf1, Brian L Egleston1, Lora S Wang1, Ranee Mehra1, Douglas B Flieder1, John A Ridge1.   

Abstract

PURPOSE: To estimate the overall survival (OS) impact from increasing time to treatment initiation (TTI) for patients with head and neck squamous cell carcinoma (HNSCC).
METHODS: Using the National Cancer Data Base (NCDB), we examined patients who received curative therapy for the following sites: oral tongue, oropharynx, larynx, and hypopharynx. TTI was the number of days from diagnosis to initiation of curative treatment. The effect of TTI on OS was determined by using Cox regression models (MVA). Recursive partitioning analysis (RPA) identified TTI thresholds via conditional inference trees to estimate the greatest differences in OS on the basis of randomly selected training and validation sets, and repeated this 1,000 times to ensure robustness of TTI thresholds.
RESULTS: A total of 51,655 patients were included. On MVA, TTI of 61 to 90 days versus less than 30 days (hazard ratio [HR], 1.13; 95% CI, 1.08 to 1.19) independently increased mortality risk. TTI of 67 days appeared as the optimal threshold on the training RPA, statistical significance was confirmed in the validation set (P < .001), and the 67-day TTI was the optimal threshold in 54% of repeated simulations. Overall, 96% of simulations validated two optimal TTI thresholds, with ranges of 46 to 52 days and 62 to 67 days. The median OS for TTI of 46 to 52 days or fewer versus 53 to 67 days versus greater than 67 days was 71.9 months (95% CI, 70.3 to 73.5 months) versus 61 months (95% CI, 57 to 66.1 months) versus 46.6 months (95% CI, 42.8 to 50.7 months), respectively (P < .001). In the most recent year with available data (2011), 25% of patients had TTI of greater than 46 days.
CONCLUSION: TTI independently affects survival. One in four patients experienced treatment delay. TTI of greater than 46 to 52 days introduced an increased risk of death that was most consistently detrimental beyond 60 days. Prolonged TTI is currently affecting survival.
© 2015 by American Society of Clinical Oncology.

Entities:  

Mesh:

Year:  2015        PMID: 26628469      PMCID: PMC4858932          DOI: 10.1200/JCO.2015.61.5906

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  47 in total

1.  Predictors of IMRT and conformal radiotherapy use in head and neck squamous cell carcinoma: a SEER-Medicare analysis.

Authors:  David J Sher; Bridget A Neville; Aileen B Chen; Deborah Schrag
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-05-17       Impact factor: 7.038

Review 2.  Impact of delay in diagnosis on survival to head and neck carcinomas: a systematic review with meta-analysis.

Authors:  J Seoane; B Takkouche; P Varela-Centelles; I Tomás; J M Seoane-Romero
Journal:  Clin Otolaryngol       Date:  2012-04       Impact factor: 2.597

3.  Waiting times for diagnosis and treatment of head and neck cancer in Denmark in 2010 compared to 1992 and 2002.

Authors:  N M Lyhne; A Christensen; M C Alanin; M T Bruun; T H Jung; M A Bruhn; J B B Jespersen; C A Kristensen; E Andersen; C Godballe; C Buchwald; T Bundgaard; J Johansen; K Lambertsen; H Primdahl; K Toustrup; J A Sørensen; J Overgaard; C Grau
Journal:  Eur J Cancer       Date:  2012-12-27       Impact factor: 9.162

4.  Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis.

Authors:  Brian O'Sullivan; Shao Hui Huang; Lillian L Siu; John Waldron; Helen Zhao; Bayardo Perez-Ordonez; Ilan Weinreb; John Kim; Jolie Ringash; Andrew Bayley; Laura A Dawson; Andrew Hope; John Cho; Jonathan Irish; Ralph Gilbert; Patrick Gullane; Angela Hui; Fei-Fei Liu; Eric Chen; Wei Xu
Journal:  J Clin Oncol       Date:  2013-01-07       Impact factor: 44.544

5.  Reduction in waiting time for diagnosis and treatment of head and neck cancer - a fast track study.

Authors:  Kasper Toustrup; Karin Lambertsen; Hanne Birke-Sørensen; Benedicte Ulhøi; Leif Sørensen; Cai Grau
Journal:  Acta Oncol       Date:  2011-01-24       Impact factor: 4.089

6.  Growth in the use of PET for six cancer types after coverage by medicare: additive or replacement?

Authors:  Bruce E Hillner; Anna N Tosteson; Yunjie Song; Tor D Tosteson; Tracy Onega; David C Goodman; Barry A Siegel
Journal:  J Am Coll Radiol       Date:  2012-01       Impact factor: 5.532

7.  Wait times for cancer surgery in the United States: trends and predictors of delays.

Authors:  Karl Y Bilimoria; Clifford Y Ko; James S Tomlinson; Andrew K Stewart; Mark S Talamonti; Denise L Hynes; David P Winchester; David J Bentrem
Journal:  Ann Surg       Date:  2011-04       Impact factor: 12.969

8.  Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.

Authors:  Christopher M Nutting; James P Morden; Kevin J Harrington; Teresa Guerrero Urbano; Shreerang A Bhide; Catharine Clark; Elizabeth A Miles; Aisha B Miah; Kate Newbold; MaryAnne Tanay; Fawzi Adab; Sarah J Jefferies; Christopher Scrase; Beng K Yap; Roger P A'Hern; Mark A Sydenham; Marie Emson; Emma Hall
Journal:  Lancet Oncol       Date:  2011-01-12       Impact factor: 41.316

9.  A "package solution" fast track program can reduce the diagnostic waiting time in head and neck cancer.

Authors:  Jesper Roed Sorensen; Jørgen Johansen; Lars Gano; Jens Ahm Sørensen; Stine Rosenkilde Larsen; Peter Bøgeskov Andersen; Anders Thomassen; Christian Godballe
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-06-18       Impact factor: 2.503

10.  Determinants of patient delay in doctor consultation in head and neck cancers (Protocol DEREDIA).

Authors:  Véronique Christophe; Tanguy Leroy; Mélanie Seillier; Camille Duthilleul; Morbize Julieron; Stéphanie Clisant; Jérôme Foncel; Fanny Vallet; Jean-Louis Lefebvre
Journal:  BMJ Open       Date:  2014-07-25       Impact factor: 2.692

View more
  101 in total

1.  Family history of cancer and head and neck cancer survival.

Authors:  Kayla R Getz; Laura S Rozek; Lisa A Peterson; Emily L Bellile; Jeremy M G Taylor; Gregory T Wolf; Alison M Mondul
Journal:  Laryngoscope       Date:  2017-03-07       Impact factor: 3.325

2.  The prognostic value of GLUT-1 staining in the detection of malignant transformation in oral mucosa.

Authors:  Roman C Brands; Olga Köhler; Stephan Rauthe; Stefan Hartmann; Harald Ebhardt; Axel Seher; Christian Linz; Alexander C Kübler; Urs D A Müller-Richter
Journal:  Clin Oral Investig       Date:  2016-09-08       Impact factor: 3.573

3.  The effect of time between diagnosis and initiation of treatment on outcomes in patients with head and neck squamous cell carcinoma.

Authors:  Luke H DeGraaff; Alexis J Platek; Austin J Iovoli; Kimberly E Wooten; Hassan Arshad; Vishal Gupta; Ryan P McSpadden; Moni Abraham Kuriakose; Wesley L Hicks; Mary E Platek; Anurag K Singh
Journal:  Oral Oncol       Date:  2019-07-30       Impact factor: 5.337

4.  Association of Insurance and Community-Level Socioeconomic Status With Treatment and Outcome of Squamous Cell Carcinoma of the Pharynx.

Authors:  Jacob Y Shin; Ja Kyoung Yoon; Aaron K Shin; Philip Blumenfeld; Miranda Mai; Aidnag Z Diaz
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-09-01       Impact factor: 6.223

5.  Timing of surgery and adjuvant radiation therapy for sinonasal malignancies: Effect of surgical approach.

Authors:  Roy Xiao; Rohan R Joshi; Qasim Husain; Jennifer R Cracchiolo; Nancy Lee; Jillian Tsai; Yao Yu; Linda Chen; Jung J Kang; Sean McBride; Nadeem Riaz; Benjamin R Roman; Ian Ganly; Viviane Tabar; Stacey T Gray; Marc A Cohen
Journal:  Head Neck       Date:  2019-07-11       Impact factor: 3.147

6.  Effect of time to initiation of postoperative radiation therapy on survival in surgically managed head and neck cancer.

Authors:  Evan M Graboyes; Elizabeth Garrett-Mayer; Mark A Ellis; Anand K Sharma; Amy E Wahlquist; Eric J Lentsch; Brian Nussenbaum; Terry A Day
Journal:  Cancer       Date:  2017-08-25       Impact factor: 6.860

7.  Having Medicaid insurance negatively impacts outcomes in patients with head and neck malignancies.

Authors:  Arash O Naghavi; Michelle I Echevarria; G Daniel Grass; Tobin J Strom; Yazan A Abuodeh; Kamran A Ahmed; Youngchul Kim; Andy M Trotti; Louis B Harrison; Kosj Yamoah; Jimmy J Caudell
Journal:  Cancer       Date:  2016-08-01       Impact factor: 6.860

8.  Multidisciplinary Clinic Management of Head and Neck Cancer.

Authors:  Melanie Townsend; Dorina Kallogjeri; Nicholas Scott-Wittenborn; Katherine Gerull; Stacy Jansen; Brian Nussenbaum
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-12-01       Impact factor: 6.223

Review 9.  Leveraging the interplay of nanotechnology and neuroscience: Designing new avenues for treating central nervous system disorders.

Authors:  Elizabeth S Smith; Joshua E Porterfield; Rangaramanujam M Kannan
Journal:  Adv Drug Deliv Rev       Date:  2019-03-04       Impact factor: 15.470

Review 10.  The Benefit of a Multidisciplinary Approach to the Patient Treated with (Chemo) Radiation for Head and Neck Cancer.

Authors:  Paolo Bossi; Salvatore Alfieri
Journal:  Curr Treat Options Oncol       Date:  2016-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.